Status:
COMPLETED
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Dyslipidemias
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
Eligibility Criteria
Inclusion
- Patients with high cholesterol eligible for treatment with baseline LDL-C level of less than or equal to 220 mg/dL
- Willingness to follow diet
Exclusion
- Triglycerides less than or equal to 400 mg/dL
- Hemoglobin A1c \>10%
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
512 Patients enrolled
Trial Details
Trial ID
NCT00645151
Start Date
April 1 2004
End Date
February 1 2005
Last Update
February 18 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
2
Pfizer Investigational Site
Curitiba, Paraná, Brazil, 80540-010
3
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil, 90035-170
4
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000